



New 2020 AHA Guidelines recommend implementation of cooling as early as possible and advanced cooling systems.

The AHA science experts review the new evidence and update the AHA's guidelines for cardiopulmonary resuscitation (CPR) and emergency cardiovascular care (ECC) have confirmed and reinforced implementation of TTM as soon as possible and the strongly advocating the use of high quality TTM Systems (with a feedback loop)

Enclosed documents

- Enclosed the Highlights from the 2020 American Heart Association Guidelines for CPR and ECC.pdf (note, slide 9 and 10).

https://cpr.heart.org/-/media/cpr-files/cpr-guidelines-files/highlights/hghlghts_2020_ecc_guidelines.pdf

- Top 10 Take-Home Messages for Adult Cardiovascular Life Support.

https://www.ahajournals.org/doi/10.1161/CIR.0000000000000916?utm_campaign=sciencenews20-21&utm_source=science-news&utm_medium=phd-link&utm_content=phd10-21-20 (note, point 8)

CEO Martin Waleij comments

“The 2020 AHA Guidelines, with the new clinical recommendations in the practice of resuscitation science for North America is in direct line with the BrainCool TTM portfolio. “

“This important update clearly shows cooling treatment shall be started as soon as possible and once the target temperature is achieved, and transferred into the ICU, a high quality TTM system, like The IQool System equipped with automated temperature feedback loop mechanisms should be used to keep the patient’s temperature at goal with minimal fluctuations.”

VP BrainCool Inc Troy Van Den Veur

“We are thrilled to see the 2020 AHA Guidelines pertaining to TTM. Early initiation, specific temperature dosage and temperature control with a high quality through all phases of TTM therapy align perfectly with the BrainCool product line”

“The IQool System by BrainCool is considered to be one of three advanced TTM systems on the US market. High Quality TTM after Cardiac Arrest, as presented earlier this year by Dr. Fabio Silvio Taccone et al (see reference 1) , should be the goal of every institution offering the therapy. We believe The IQool™ System provides the greatest opportunity to deliver High Quality TTM by offering clinical and significant financial advantages.”

The AHA Guideline is considered the gold standard with regard to clinical recommendations in the practice of resuscitation science not only in North America, but around the world. Top Take-Home Message on Post–Cardiac Arrest TTM is as follows:

- Targeted temperature management remains important and prompt initiation of targeted temperature management is necessary for all patients who do not follow commands after return of spontaneous circulation to ensure optimal functional and neurological outcome; begin 32-36C for 24 hours by using a cooling device with feedback loop.

- The 2020 Guidelines strongly advised recommendations for performance of TTM as follows:

We recommend TTM for adult who do not follow commands after ROSC from OHCA with any initial rhythm.

We recommend TTM for adult who do not follow commands after ROSC from IHCA with initial nonshockable rhythm.

We recommend TTM for adult who do not follow commands after ROSC from IHCA with initial shockable rhythm.

CEO Martin Waleij concludes

The new guidelines will also serve as an important tool and an important enabler in our pursuit to approve The RhinoChill™ System for the US market through the ongoing De Novo 510 k process. BrainCool continues the mission that all cardiac arrest patients should be cooled at the earliest opportunity in a hospital or at field emergency setting with the aim and objective to improve survival and neurological recovery. Our solution the BrainCell concept will target, the problem with limitations of previous products in the treatments chain of cardiac arrest patients, as well as expanding the concept into neurology.

BrainCell, our solution linking RhinoChill™ (pending US approval) and IQool, will target the problem with limitations of previous products in the treatment chain of cardiac arrest patients, as well as expanding the concept into neurology. This will enable health-care personnel to easily, effectively and immediately initiate cooling of the brain after Sudden Cardiac Arrest (SCA). The BrainCell solution ensures long-term cooling during multiple days, completing the chain of treatment.”

About the BrainCell concept

BrainCool continue their mission that all cardiac arrest patients should be cooled at the earliest opportunity in a hospital or at field emergency setting with the aim and objective to improve survival and neurological recovery.

Our solution the BrainCell concept will target, the problem with limitations of previous products in the treatments chain of cardiac arrest patients, as well as expanding the concept into neurology.

By the integration of RhinoChill™ and IQool™, BrainCell enables health-care personnel to easily and effectively and most importantly immediately initiate cooling of the brain immediately after the SCA (RhinoChill™). The BrainCell ensures long-term cooling during multiple days (IQool™), completing the chain of treatment.”

RhinoChill System is pending FDA approval, with a De Novo 510 k designation.

Reference 1 Taccone et al - <https://pubmed.ncbi.nlm.nih.gov/31907075/>

About the BrainCell concept

BrainCool continue their mission that all cardiac arrest patients should be cooled at the earliest opportunity in a hospital or at field emergency setting with the aim and objective to improve survival and neurological recovery.

Our solution the BrainCell concept will target, the problem with limitations of previous products in the treatments chain of cardiac arrest patients, as well as expanding the concept into neurology.

By the integration of RhinoChill™ and IQool™, BrainCell enables health-care personnel to easily and effectively and most importantly immediately initiate cooling of the brain immediately after the SCA (RhinoChill™). The BrainCell ensures long-term cooling during multiple days (IQool™), completing the chain of treatment.”

This disclosure contains information that BrainCool is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 22-10-2020 10:04 CET.

For more information

Martin Waleij - CEO
+46 - 733 -93 70 76
E-mail: martin.waleij@braincool.se

About BrainCool AB (publ)

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Pain Management. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Spotlight Stock Market.